Terremoto Biosciences patents AKT1 inhibitors for cancer Feb. 26, 2025 Terremoto Biosciences Inc. has synthesized new 3 H -imidazo[4,5- b ]pyridine compounds acting as RAC-α serine/threonine-protein ...
This is achieved by the interaction between the potassium ion channel AKT1 and the potassium transporter HAK5. "Although HAK5 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback